The safety of tadalafil in the treatment of erectile dysfunction.
- Author:
Hao-yang WANG
1
;
Yu-feng HUANG
Author Information
1. Department of Reproduction & Genetics, PLA Research Institute of Clinical Laboratory Medicine, Nanjing General Hospital of Nanjing Command, PLA, Nanjing, Jiangsu 210002, China.
- Publication Type:Journal Article
- MeSH:
Back Pain;
chemically induced;
Carbolines;
adverse effects;
therapeutic use;
Erectile Dysfunction;
drug therapy;
Headache;
chemically induced;
Humans;
Male;
Phosphodiesterase Inhibitors;
adverse effects;
therapeutic use;
Tadalafil
- From:
National Journal of Andrology
2007;13(8):762-764
- CountryChina
- Language:Chinese
-
Abstract:
The cyclic nucleotide (cGMP) signalling pathway mediates the smooth-muscle relaxing effects of nitric oxide necessary for normal erectile function. Down-regulation of this pathway is the pathophysiological pivot of many forms of erectile dysfunction (ED) and leads to the development of some chronic diseases, such as hypertension and type 2 diabetes mellitus. Therefore, selective inhibition of the enzyme that catalyses the degradation of cGMP promotes erectile responses to sexual stimulation. Recently, a new phosphodiesterase type 5 (PDE-5) inhibitor tadalafil has emerged, which has a prolonged half-life. Here is a review of recent studies on the safety of tadalafil in the treatment of ED.
